Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy
About this study
This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.
- Condition
- Obesity & Overweight, Type 2 Diabetes, Type 2 Diabetes (Adult Onset), Obesity Type 2 Diabetes Mellitus, Dehydration
- Tested
- Hydration Plus, Control
- Sponsor
- State University of New York at Buffalo
Who can join
- Age
- 18 to 60 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Maximum age: 60 years
- Study condition: Obesity & Overweight, Type 2 Diabetes, Type 2 Diabetes (Adult Onset), Obesity Type 2 Diabetes Mellitus, Dehydration
- Adults aged 18-60
- Recently prescribed a GLP-1RA (within one week of prescription)
- Fluent in English
- Willing to complete the study protocol
Exclusion 7
- Children and adults \> 60 years of age
- Those not taking a GLP-1RA
- Those who have been on a GLP-1RA longer than one week
- Not fluent in English
- Those who are pregnant or planning on becoming pregnant during the duration of the study
- Unwilling to comply with study protocol
- People with cardiac implants
Where
1 site, 1 recruiting
State University of New York at Buffalo, South Campus
Buffalo, New York, United States
Potential match only. Final eligibility is determined by the study team.